Petaluma, CA – According to filings with the U.S. Securities and Exchange Commission, Spectrum Antimicrobials is raising $28,750,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Hojabr Alimi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Spectrum Antimicrobials
At Spectrum Antimicrobials we are an infection treatment and control solutions company that has created two significant broad spectrum (non-antibiotic based) chemistries to combat viral, bacterial, fungal and mold caused infection in wounds, surgical sites, eyes, body cavities and in the lung without causing antibiotic resistance. Our platform technologies have the potential to significantly reduce the $30 billion spent in the US each year on antibiotic resistant infections and over $80 billion per year on the various influenza flus. Our platforms may replace antiquated chemistries and therapies used on over 2 million bacterial infections and on over 40 million influenza cases resulting in more than 100,000 patient deaths each year in just the United States.

To learn more about Spectrum Antimicrobials, visit http://spectrumantimicrobials.com/

Contact:
Hojabr Alimi, Chief Executive Officer
707-668-7600
halimi@spectrumantimicrobials.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved